State Street Corp Protalix Bio Therapeutics, Inc. Transaction History
State Street Corp
- $2.59 Trillion
- Q2 2025
A detailed history of State Street Corp transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 444,239 shares of PLX stock, worth $728,551. This represents 0.0% of its overall portfolio holdings.
Number of Shares
444,239Holding current value
$728,551% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding PLX
# of Institutions
67Shares Held
8.7MCall Options Held
180KPut Options Held
10.6K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$2.65 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$1.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.36 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$813,7940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$795,0680.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $81.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...